• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

CFO

COPD chronic obstructive pulmonary disease lungs
Pharma

GSK revs up launch plans after Nucala's FDA approval in COPD

The thumbs-up makes Nucala the second biologic approved in COPD and the third new therapy cleared for the disease by the FDA in less than a year.
Fraiser Kansteiner May 22, 2025 3:10pm
Stacks of paper on desk in office

Teva plots layoffs as restructuring drive enters new phase

May 8, 2025 9:55am
new ceo hiring fired executive leader chutes

Lilly taps longtime company veteran to fill finance chief role

Sep 9, 2024 10:28am
hiring new hire

Eli Lilly names company vet Gordon Brooks as interim CFO

Jul 10, 2024 10:48am
Eli Lilly

Google's search for a CFO lands on Eli Lilly's Anat Ashkenazi

Jun 5, 2024 11:05am
jnj

J&J takes major hit from litigation cost in 2023's first quarter

Apr 18, 2023 11:15am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings